American Academy of Neurology® April 2020LikeFollowShareA Phase 1 Study of PBT434, a Novel Small Molecule Inhibitor of α-Synuclein Aggregation, in Adult and Older Adult Volunteers (4871)https://www.neurology.org/doi/10.1212/WNL.94.15_supplement.4871Share your feedbackQuestions (0)Post questionYour question will be sent privately to Alterity Therapeutics. The company may choose to make this question public.Start the conversationAsk Alterity Therapeutics a question about this update.DiscoverShare your feedbackDiscover